tradingkey.logo

BRIEF-European Commission Approves Rybrevant In Combination With Lazcluze For First-Line Treatment Of Patients With EGFR-Mutated Advanced Non-Small Cell Lung Cancer

ReutersDec 30, 2024 11:58 AM

- Johnson & Johnson JNJ.N:

  • J&J: EC APPROVES RYBREVANT IN COMBINATION WITH LAZCLUZE FOR FIRST-LINE TREATMENT OF PATIENTS WITH EGFR-MUTATED ADVANCED NON-SMALL CELL LUNG CANCER

Further company coverage: JNJ.N

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI